MedPath

Dacarbazine

Generic Name
Dacarbazine
Drug Type
Small Molecule
Chemical Formula
C6H10N6O
CAS Number
4342-03-4
Unique Ingredient Identifier
7GR28W0FJI
Background

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication

For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions
Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Clinical Trials
Related News

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

First Posted Date
2010-12-01
Last Posted Date
2015-08-13
Lead Sponsor
Fondazione Michelangelo
Target Recruit Count
331
Registration Number
NCT01251107
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Phase 3
Completed
Conditions
Cancer
Interventions
First Posted Date
2010-10-25
Last Posted Date
2017-10-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
251
Registration Number
NCT01227889
Locations
🇪🇸

GSK Investigational Site, Sevilla, Spain

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Phase 2
Terminated
Conditions
Melanoma
Interventions
First Posted Date
2010-09-13
Last Posted Date
2016-02-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
7
Registration Number
NCT01200342
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

Phase 2
Completed
Conditions
Malignant Melanoma
Interventions
First Posted Date
2010-07-16
Last Posted Date
2017-04-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT01164007
Locations
🇮🇹

Istituto Europeo Di Oncologia, Milano, Lombardia, Italy

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2010-06-29
Last Posted Date
2023-08-22
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
64
Registration Number
NCT01152788
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada

🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 16 locations

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase 2
Completed
Conditions
Iris Melanoma
Recurrent Uveal Melanoma
Stage IV Uveal Melanoma
Medium/Large Size Posterior Uveal Melanoma
Ocular Melanoma With Extraocular Extension
Small Size Posterior Uveal Melanoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
First Posted Date
2010-06-14
Last Posted Date
2017-07-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT01143402
Locations
🇨🇦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

🇺🇸

Mount Sinai Medical Center, Miami Beach, Florida, United States

🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 30 locations

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase 1
Completed
Conditions
Stage IV Melanoma
Interventions
First Posted Date
2010-05-31
Last Posted Date
2016-10-10
Lead Sponsor
Eisai Inc.
Target Recruit Count
97
Registration Number
NCT01133977

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Biological: Bleomycin Sulfate
Drug: Radiation Therapy
Radiation: Fludeoxyglucose F-18
Procedure: computed tomography
Procedure: Positron Emission Tomography
First Posted Date
2010-05-28
Last Posted Date
2021-06-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
164
Registration Number
NCT01132807
Locations
🇺🇸

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States

🇺🇸

UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States

🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 92 locations

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Phase 2
Completed
Conditions
Iris Melanoma
Recurrent Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Ciliary Body and Choroid Melanoma, Small Size
Interventions
Biological: recombinant interferon alfa-2b
Other: laboratory biomarker analysis
First Posted Date
2010-04-09
Last Posted Date
2019-02-26
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
38
Registration Number
NCT01100528
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

First Posted Date
2010-02-02
Last Posted Date
2014-12-18
Lead Sponsor
Seagen Inc.
Target Recruit Count
51
Registration Number
NCT01060904
Locations
🇺🇸

MD Anderson Cancer Center / University of Texas, Houston, Texas, United States

🇺🇸

UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy